Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00453414

Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Actelion · Industry
Sex
All
Age
3 Years – 18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety and effectiveness of iloprost for PAH in children who are between the ages of 3 and 18 years old.

Conditions

Interventions

TypeNameDescription
DRUGIloprost Inhalation Solution (Ventavis)

Timeline

Start date
2006-07-01
Primary completion
2006-10-01
Completion
2006-10-01
First posted
2007-03-29
Last updated
2010-02-15

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00453414. Inclusion in this directory is not an endorsement.